Europe/Sponsors

From 2013.igem.org

(Difference between revisions)
 
(5 intermediate revisions not shown)
Line 7: Line 7:
<li><font size="5"><b>iGEM 2013 Europe Platinum Partners</b></font></li>
<li><font size="5"><b>iGEM 2013 Europe Platinum Partners</b></font></li>
<br/><br/>
<br/><br/>
-
<A href="http://www.biomerieux.com/" title="Biomérieux"><IMG Align="left" src="https://static.igem.org/mediawiki/2013/1/11/Logo_biomerieux.jpg" style="margin-right:50px;" border="0" alt="Biomérieux" width="400"></A>
+
<table>
-
<p>Biomérieux is established in each continent and in more than 160 countries and has more than 1000 collaborators.
+
<tr>
-
Biomérieux is a world actor in the field of:<br/>
+
<td><A href="http://www.biomerieux.com/" title="bioMérieux"><IMG Align="left" src="https://static.igem.org/mediawiki/2013/5/56/EXE-LOGO-VA.jpg" style="margin-right:50px;" border="0" alt="bioMérieux" width="430" /></A></td>
 +
 +
<td><p style="line-height:15px;"><b><i>Pioneering Diagnostics</b></i><br/>
 +
A world leader in the field of <i><b>in vitro</i> diagnostics</b> for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors.<br/>
 +
With more than 7,400 employees in the world, bioMérieux provides diagnostic solutions (reagents, instruments, software and services) which determine the source of disease and contamination to <b>improve patient health</b> and <b>ensure consumer safety</b>.
 +
<ul>
 +
<li style="line-height:15px;">Its products are used for diagnosing <b>infectious diseases</b> (HIV, hepatitis, tuberculosis, etc.) and providing high medical value results for <b>cancer</b> screening and monitoring and <b>cardiovascular emergencies</b>.</li>
 +
<li style="line-height:15px;">They are also used for detecting microorganisms in <b>agri-food, pharmaceutical and cosmetic products</b>.</li>
 +
</ul>
 +
<b><i>What are in vitro diagnostics?</b></i>
<ul>
<ul>
-
<li><b>In vitro diagnosis</b> for more than 45 years and offers solutions of diagnosis: reagents to conduct biological tests to be able to identify different types of bacteria, viruses and to measure markers or specific    hormones; instruments for automated testing and software to interpret the results of biological tests, </li><br/>
+
<li style="line-height:15px;">Analyzing a biological sample to detect and measure the presence of disease-causing agents (bacteria, viruses,…) or substances produced by the body.</li>
-
     
+
    • Essential first step before any clinical diagnosis.
-
<li><b>Clinical application for the diagnosis of infectious diseases</b> such as     hepatitis, HIV, tuberculosis ans respiratory infections but also    cardiovascular diseases and cancer based on biological samples    analysis like blood, saliva, urine…,</li><br/>
+
 
 +
<li style="line-height:15px;">Analyzing a food, drug or air sample to monitor and confirm the quality of the production process.</li>  
 +
    • Necessary to ensure safety in food as well as in pharmaceutical and cosmetic products.
-
<li><b>Industrial application for the analysis of industrial samples</b> such as food,    pharmaceutical and cosmetic products or environmental samples such as    water, air surface to determine microbiological quality.</li>
 
</ul>
</ul>
-
<br/>
+
</td>
 +
</tr>
 +
</table>
 +
</p>
 +
 
<br/>
<br/>
<br/>
<br/>
Line 24: Line 38:
<li><font size="5"><b>iGEM 2013 Europe Gold Partners</b></font></li>
<li><font size="5"><b>iGEM 2013 Europe Gold Partners</b></font></li>
<br/><br/>
<br/><br/>
-
<A href="http://www.erasynbio.eu/" title="ERASynbio"><IMG Align="left" src="https://static.igem.org/mediawiki/2013/c/c2/Logo-erasynbio.jpg" style="margin-right:50px;" border="0" alt="ERASynbio" width="350" hspace="20"/></A>
+
<table>
 +
<tr>
 +
<td width=50%><A href="http://www.erasynbio.eu/" title="ERASynbio"><IMG Align="left" src="https://static.igem.org/mediawiki/2013/c/c2/Logo-erasynbio.jpg" style="margin-right:50px;" border="0" alt="ERASynbio" width="400"/></A></td>
-
<p>The central idea of ERASynBio is <b>to promote the robust development of Synthetic Biology</b> by structuring and coordinating national efforts and investment. ERASynBio will develop a strategic research agenda / white paper, which will support the emergence of national Synthetic Biology programmes and which will lay the ground for transnational funding activities via joint calls in the project. ERASynBio will stimulate and tackle the interdisciplinary nature and immaturity by offering training and educational possibilities, establishing an interdisciplinary advisory board and inviting observers of other funding organisations. Tight <b>collaboration between academia and industry</b> aiming to fertilize the innovation process will occur on several levels. To adhere to ethical, legal and societal aspects as well as to technical issues like standardisation and infrastructure development ERASynBio will trace and integrate the ongoing work and research on these framework conditions and integrate them in the strategic research.<p/>
+
<td width=50%><p>The central idea of ERASynBio is <b>to promote the robust development of Synthetic Biology</b> by structuring and coordinating national efforts and investment. ERASynBio's main activities include developing a strategic research agenda / white paper, which supports the emergence of national Synthetic Biology programmes and lays the ground for transnational funding activities via joint calls in the project. ERASynBio stimulates and tackles the interdisciplinary nature and immaturity of the field by offering training and educational possibilities, establishing an interdisciplinary advisory board and inviting observers of other funding organisations. Tight <b>collaboration between academia and industry</b> aiming to fertilize the innovation process is occuring on several levels. To adhere to ethical, legal and societal aspects as well as to technical issues like standardisation and infrastructure development ERASynBio is tracing the ongoing work and research on these framework conditions, integrating them in its strategic documents and activities. </td>
-
<br/>
+
 
 +
 
 +
</tr>
 +
</table>
 +
<br/><br/>
<li><font size="5"><b>iGEM 2013 Europe Governmental Partners</b></font></li>
<li><font size="5"><b>iGEM 2013 Europe Governmental Partners</b></font></li>

Latest revision as of 18:56, 6 September 2013


  • iGEM 2013 Europe Platinum Partners


  • bioMérieux

    Pioneering Diagnostics
    A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more than 150 countries through 41 subsidiaries and a large network of distributors.
    With more than 7,400 employees in the world, bioMérieux provides diagnostic solutions (reagents, instruments, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety.

    • Its products are used for diagnosing infectious diseases (HIV, hepatitis, tuberculosis, etc.) and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies.
    • They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
    What are in vitro diagnostics?
    • Analyzing a biological sample to detect and measure the presence of disease-causing agents (bacteria, viruses,…) or substances produced by the body.
    • • Essential first step before any clinical diagnosis.
    • Analyzing a food, drug or air sample to monitor and confirm the quality of the production process.
    • • Necessary to ensure safety in food as well as in pharmaceutical and cosmetic products.



  • iGEM 2013 Europe Gold Partners


  • ERASynbio

    The central idea of ERASynBio is to promote the robust development of Synthetic Biology by structuring and coordinating national efforts and investment. ERASynBio's main activities include developing a strategic research agenda / white paper, which supports the emergence of national Synthetic Biology programmes and lays the ground for transnational funding activities via joint calls in the project. ERASynBio stimulates and tackles the interdisciplinary nature and immaturity of the field by offering training and educational possibilities, establishing an interdisciplinary advisory board and inviting observers of other funding organisations. Tight collaboration between academia and industry aiming to fertilize the innovation process is occuring on several levels. To adhere to ethical, legal and societal aspects as well as to technical issues like standardisation and infrastructure development ERASynBio is tracing the ongoing work and research on these framework conditions, integrating them in its strategic documents and activities.



  • iGEM 2013 Europe Governmental Partners

  • Ministère de l'Enseignement Supérieur et de la Recherche Région Rhone-Alpes Grand Lyon


  • iGEM 2013 Europe Academic Partners


  • INSA de Lyon ENS de Lyon CPE de Lyon Université de Lyon BioDocs Lyon


    Lyon Biopole Finovi